Atsena touts one-year data for congenital eye disease therapy as it seeks partner for pivotal study
Atsena Therapeutics’ gene therapy improved vision in a handful of patients with certain mutations of Leber congenital amaurosis, a disorder that causes severe vision loss or blindness from birth.
However, the company said Monday it’s seeking a partner to move the treatment into pivotal studies after announcing in October that it laid off staff and decided to focus on a different eye disease gene therapy to cut costs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
